Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PFS for BelCaP will most likely reach endpoint of +60%

|Includes: ALTH, Spectrum Pharmaceuticals, Inc. (SPPI)

Spectrums partner Topotarget had a few days a telephone conference relating to the Q3 report and in the following QA session it was asked what the target number of patients is in the ongoing CUP trial (i.e. how many that must pass into progression before data is evaluated) and the anser was 68.

Based on this, it is possible to estimtate values of median PFS for the BelCaP arm given some median PFS values for the CaP arm.

As can be seen in the link, BelCaP has a very good chance to meet the endpoint which is set to +60% and it is also possible that the combination shows extraordinary results...